BioCryst to acquire Astria Therapeutics for 0.59 shares + $8.55 cash per share; Q3 ORLADEYO strong

BIOCRYST PHARMACEUTICALS INC

Merger: each Astria share → 0.59 BCRX shares + $8.55 cash; expected close Q1 2026.
Blackstone provides $550M senior secured credit facility ($350M term loan + $50M committed delayed draw + $150M uncommitted) to fund deal.
Q3 2025: ORLADEYO demand strong with no impact from new competition (no specific figures given).
Astria CEO Jill Milne appointed to BioCryst board effective at merger close; receives $500K equity grant.
BioCryst paid off and terminated April 2023 loan agreement with BioPharma Credit PLC.

item 1.01item 2.02item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.